Previous 10 | Next 10 |
This Buffett holdings list from Kiplinger first appeared on 5/17/22 online. YCharts and Dogs of The Dow also track this Buffett/Berkshire batch. Here is your update from 7/18/22 YCharts data. 32 of 49 current Berkshire Hathaway-owned stocks pay dividends. As of 7/18/22, the top ten ra...
NEW YORK, July 15, 2022 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2022 of $0.19 per Class A ordinary share. The dividend will be paid on September 15, 2022, to shareholders of record at...
NEW YORK, July 14, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2022 financial results on Thursday, August 4, 2022 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at...
Royalty Pharma ( NASDAQ: RPRX ) has agreed to buy a royalty interest in pulmonary disease and asthma treatment Trelegy Ellipta from Theravance Biopharma ( NASDAQ: TBPH ) and Innoviva ( NASDAQ: INVA ) for $1.3B in cash up front and up to $300M in milestone payment...
Further diversifies Royalty Pharma’s portfolio with market-leading respiratory therapy Expected to significantly add to long-term Adjusted Cash Receipts growth ( 1) ( non-GAAP) NEW YORK, July 13, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma pl...
Theravance Biopharma to Sell TRELEGY ELLIPTA Royalty Interests to Royalty Pharma for Approximately $1.1 Billion in Upfront Cash with Over $1.5 Billion in Potential Total Value PR Newswire Over $1.5 Billion in Potential Total Value, Including Approximately $1.1 ...
Attractive, precision oncology therapy with long patent duration added to portfolio Blueprint Medicines to receive $175 million upfront and $165 million in potential milestone payments NEW YORK, June 30, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today an...
Blueprint Medicines Announces Transformative $1.25 Billion Strategic Financing Collaborations with Sixth Street and Royalty Pharma PR Newswire Strengthens balance sheet with significant non-dilutive, low-cost capital Expands ability to bring the promise of pr...
France's Ipsen (OTCPK:IPSEY) (OTCPK:IPSEF) is acquiring Cambridge, Mass.-based cancer drug maker Epizyme (NASDAQ:EPZM) for $247M plus contingent value right (CVR). Ipsen will begin an all-cash tender offer to acquire all outstanding shares of Epizyme (EPZM) for $1.45/share plus a CV...
NEW YORK, June 08, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to present at the Goldman Sachs 43 rd Annual Global Healthcare Conference on June 14, 2022 at 2:20 p.m. ET. The webcast will be accessible from Royalty Pharma’...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Molly Sawaya as Executive Vice President, Head of Human Capital. Molly joins Royalty Pharma from Hudson Bay Capital, where she was a Managing Director and Head of Colleague Experie...
2024-07-24 08:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, July 19, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2024 financial results on Thursday, August 8, 2024 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 ...